Markets:

Overview

News

Currencies

International

Treasuries

Appili Therapeutics Inc (OP:APLIF)

0.0055 UNCHANGED

Delayed Quote Updated: 2:57 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Appili Therapeutics Inc

< Previous 1 2 3 Next >

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

April 03, 2023

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

February 14, 2023

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

January 17, 2023

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

January 13, 2023

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

November 14, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

November 10, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

September 22, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

August 12, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

August 02, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

June 29, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

April 27, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

April 13, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

February 28, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022

February 14, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

February 08, 2022

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

November 19, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer

November 12, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™

November 12, 2021

From Appili Therapeutics Inc.

Via Business Wire

Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate ↗

October 05, 2021

Aditxt Inc (NASDAQ: ADTX) has agreed to acquire AiPharma Global Holdings LLC, focused on discovering, developing, and commercializing antiviral therapies. AiPharma...

Via Benzinga

Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction

September 29, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19

September 23, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients

September 20, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients

September 17, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders

September 08, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022

August 13, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022

June 24, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil

June 17, 2021

From Appili Therapeutics Inc.

Via Business Wire

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021

April 19, 2021

From Appili Therapeutics Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.